Jon Smythe

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Randomized Controlled Clinical Trial of Allogeneic Mesenchymal Stromal Cell Infusion in Diabetic Kidney Disease.

Randomized Controlled Clinical Trial of Allogeneic Mesenchymal Stromal Cell Infusion in Diabetic Kidney Disease.

Journal: Kidney international reports
Published: December 17, 2025

Design and validation of a GMP stem cell manufacturing protocol for MPSII hematopoietic stem cell gene therapy.

Design and validation of a GMP stem cell manufacturing protocol for MPSII hematopoietic stem cell gene therapy.

Journal: Molecular therapy. Methods & clinical development
Published: February 05, 2024

Repair of Acute Respiratory Distress Syndrome in COVID-19 by Stromal Cells (REALIST-COVID Trial): A Multicenter, Randomized, Controlled Clinical Trial.

Repair of Acute Respiratory Distress Syndrome in COVID-19 by Stromal Cells (REALIST-COVID Trial): A Multicenter, Randomized, Controlled Clinical Trial.

Journal: American journal of respiratory and critical care medicine
Published: May 08, 2023

Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM).

Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM).

Journal: Journal of the American Society of Nephrology : JASN
Published: March 22, 2023

Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) trial: A phase 1 trial.

Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) trial: A phase 1 trial.

Journal: EClinicalMedicine
Published: August 06, 2021

Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial.

Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial.

Journal: Trials
Published: June 23, 2021

Letter to the Editor Regarding "Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients".

Letter to the Editor Regarding "Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients".

Journal: Transplantation and cellular therapy
Published: October 15, 2020

Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.

Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.

Journal: Trials
Published: May 12, 2020

Non-invasive imaging reveals conditions that impact distribution and persistence of cells after in vivo administration.

Non-invasive imaging reveals conditions that impact distribution and persistence of cells after in vivo administration.

Journal: Stem cell research & therapy
Published: June 22, 2018

Measuring the resting naive sub-population of T-regulatory cells improves prediction of suppressive function of clinical grade T-regulatory products.

Measuring the resting naive sub-population of T-regulatory cells improves prediction of suppressive function of clinical grade T-regulatory products.

Journal: Cytotherapy
Published: July 20, 2016

An innovative method to generate a Good Manufacturing Practice-ready regulatory T-cell product from non-mobilized leukapheresis donors.

An innovative method to generate a Good Manufacturing Practice-ready regulatory T-cell product from non-mobilized leukapheresis donors.

Journal: Cytotherapy
Published: March 13, 2014

A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.

A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.

Journal: Cancer chemotherapy and pharmacology
Published: August 02, 2013
Showing 1-12 of 14

Last Updated: 09/26/2026